In contrast, a recent study showed that shRNA-mediated knock-down of Flt3 increases the latency of MLL-AF9 induced leukemias in transplanted mice [11], supporting the notion that Flt3 is a worthy drug target. The gene discussed is FLT3; the disease is leukemia.